NCI-H2170 Xenograft Model Service for NSCLC

The NCI-H2170 xenograft model provides a robust preclinical platform for investigating lung squamous cell carcinoma (LUSC), a molecularly distinct NSCLC subtype characterized by FGFR1 and SOX2 amplifications, elevated PD-L1 expression, and intrinsic resistance to EGFR-targeted agents. Alfa Cytology delivers comprehensive NCI-H2170 xenograft model services spanning authenticated cell banking, tumor establishment, compound administration, and multi-parameter endpoint analysis to generate reproducible, publication-quality data that advance your preclinical LUSC therapeutic pipeline.

Overview of NCI-H2170 Xenograft Model for NSCLC

The NCI-H2170 cell line was established from a primary lung squamous cell carcinoma and is classified as a moderately differentiated pulmonary squamous carcinoma with epithelial morphology. Genetically, this line harbors focal amplifications in SOX2 and FGFR1—two of the most prevalent oncogenic drivers in LUSC—along with activating mutations in RHOA and TP53, while remaining wild-type for EGFR and negative for ALK rearrangements. This molecular landscape positions NCI-H2170 as an archetypal model for the squamous NSCLC subtype, which accounts for approximately 25–30% of all lung cancers and is typically devoid of the actionable mutations that characterize lung adenocarcinoma. The line also exhibits high PD-L1 expression and moderate activation of PI3K/AKT and MAPK signaling cascades, further broadening its utility for immuno-oncology and pathway-directed therapeutic investigations.

Fig 1. Ectopic DDX36 expression enhanced proliferation, migration and invasion of lung squamous cells, supporting DDX36 as an oncogenic driver in the squamous NSCLC model panel containing NCI-H2170. (Jiang, Xia, et al., 2026)

In immunodeficient murine hosts, NCI-H2170 cells form reproducible subcutaneous tumors with consistent take rates and moderate growth kinetics, typically becoming palpable within two weeks post-inoculation. The xenograft model has demonstrated significant responses to platinum-based chemotherapeutics, FGFR1 inhibitors, PI3K/mTOR pathway blockers, and TROP2-directed antibody-drug conjugates, with tumor growth inhibition correlating to modulation of downstream signaling effectors. Endpoint tissues retain squamous differentiation markers including cytokeratin 5/6 and p63, while remaining negative for TTF-1, thereby preserving histopathological fidelity. These attributes render the NCI-H2170 xenograft an indispensable tool for advancing LUSC-specific therapeutic strategies from target validation to lead optimization.

Cell Line Information: NCI-H2170

NCI-H2170 is a human lung squamous cell carcinoma line with epithelial morphology and robust tumorigenicity in immunodeficient mice. The line carries hallmark molecular alterations of the LUSC subtype, including SOX2 and FGFR1 amplifications, RHOA and TP53 mutations, and high PD-L1 expression, while lacking EGFR mutations and ALK rearrangements. The table below summarizes the key biological and technical attributes of the NCI-H2170 cell line.

Our Services

Alfa Cytology provides fully integrated NCI-H2170 xenograft model services customized to your preclinical LUSC research objectives. Our scientific team oversees every phase—from authenticated cell line expansion and mycoplasma screening to tumor inoculation, randomized cohort allocation, compound dosing, and comprehensive endpoint analysis—ensuring regulatory compliance, data traceability, and transparent reporting throughout your study.

Workflow of NCI-H2170 Xenograft Model Construction

Construction of the NCI-H2170 xenograft model follows a systematic, quality-assured workflow designed to ensure reproducible tumor growth, ethical compliance, and robust data generation. Each stage is executed under GLP-aligned standard operating procedures with full documentation and batch traceability from cell banking to final report delivery.

1. Cell Line Authentication and Expansion: NCI-H2170 cells are revived from authenticated cryopreserved master stocks and expanded under sterile conditions. Short tandem repeat (STR) profiling, mycoplasma testing, and viability assessment are performed to confirm identity and purity. FGFR1 and SOX2 amplification status is verified by FISH or qPCR prior to inoculation.
2. Animal Preparation and Cohort Randomization: Immunodeficient mice are quarantined and acclimated for a minimum of five days under controlled environmental conditions. Animals are randomized into vehicle and treatment groups based on body weight, with all protocols approved by the institutional animal care and use committee (IACUC).
3. Tumor Cell Inoculation: A suspension of 2–5 × 10⁶ NCI-H2170 cells in 100–200 µL of ice-cold PBS or PBS/Matrigel (1:1) is injected subcutaneously into the right flank of each mouse using a sterile 25-gauge needle. Orthotopic lung implantation is available upon request for studies requiring organ-specific tumor microenvironment interactions.
4. Longitudinal Tumor Monitoring: Tumor dimensions are measured with digital calipers twice weekly beginning from the appearance of palpable masses. Tumor volume is calculated using the modified ellipsoid formula: length × (width)² / 2. Body weight and clinical observations are recorded concurrently to assess treatment tolerability.
5. Test Article Administration: Investigational compounds are administered according to the study-specific regimen via oral gavage, intraperitoneal, intravenous, or subcutaneous routes. Vehicle control groups receive the equivalent formulation without active agent. Combination arms and dose-escalation cohorts are configured as specified in the study protocol.
6. Endpoint Assessment and Tissue Collection: Mice are humanely euthanized upon reaching the predetermined endpoint—typically when tumor volume approaches 1,500 mm³ or at a fixed study duration. Tumors are excised, weighed, and subdivided for formalin-fixed paraffin-embedded (FFPE) histology, snap-frozen molecular analysis, and single-cell dissociation for flow cytometry.
7. Data Analysis and Study Reporting: Tumor growth curves, tumor growth inhibition (TGI) percentages, and statistical comparisons between treatment groups are generated using validated biostatistical platforms. A comprehensive study report including raw data, methodology, representative images, and mechanistic interpretation is delivered to the sponsor.

Fig 2. NCI-H2170 xenograft model construction workflow.

Case Study-NCI-H2170 Xenograft Model Development

In a recent preclinical program, the NCI-H2170 xenograft model was employed to evaluate the anti-tumor efficacy of a TROP2-directed antibody-drug conjugate in combination with a checkpoint inhibitor for PD-L1-high lung squamous cell carcinoma. Following subcutaneous inoculation of NCI-H2170 cells into athymic nude mice, measurable tumors were established within 14 days with a take rate exceeding 90%. Animals were randomized into vehicle, monotherapy, and combination treatment arms once mean tumor volume reached approximately 150 mm³. Longitudinal monitoring revealed dose-dependent tumor growth inhibition across treatment cohorts, with the combination arm demonstrating superior suppression compared to either monotherapy alone. Endpoint pharmacodynamic analysis showed marked reduction of tumor cell proliferation as assessed by Ki-67 immunohistochemistry, alongside modulation of downstream TROP2 signaling markers in tumor lysates from combination-treated animals. Histopathological examination confirmed preserved squamous differentiation with CK5/6 and p63 positivity, and treatment-associated reductions in tumor cell density were observed in responder groups. These preclinical findings supported the mechanistic rationale for advancing the combination regimen into subsequent development stages.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your NCI-H2170 xenograft studies grants access to a scientifically rigorous, operationally transparent preclinical platform. Our integrated service infrastructure is designed to deliver high-fidelity, actionable data within competitive timelines.

• Authenticated cell repositories with routine STR profiling, mycoplasma screening, and driver gene verification to ensure genetic fidelity and experimental reproducibility.
• Customizable study designs including subcutaneous, orthotopic, and metastatic model configurations tailored to your mechanistic and therapeutic questions.
• Real-time tumor growth tracking via digital calipers or optional non-invasive imaging modalities such as bioluminescence and micro-CT upon request.
• Comprehensive endpoint analysis spanning histopathology, immunohistochemistry (CK5/6, p63, TTF-1, Ki-67, PD-L1), Western blot, qPCR, RNA sequencing, and multiplex cytokine profiling.
• Dedicated project scientists providing weekly progress updates, direct raw data access, and regulatory-compliant documentation packages.
• Streamlined study execution with standard tumor establishment and treatment phases typically completed within 4–6 weeks from project initiation.

Contact Us

Ready to advance your lung squamous cell carcinoma research with a validated NCI-H2170 xenograft model? Reach out to the Alfa Cytology scientific team today to discuss your study design, receive a customized proposal, and discover how our preclinical expertise can accelerate your LUSC therapeutic development. Contact us now to schedule a consultation and move your program forward with confidence.

For research use only. Not intended for any clinical use.